Clinical trial
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory…
NCT00478959 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00478959 |
|---|---|
| Title | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma |
| Official title | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin Disease |
| Intervention type | Drug |
| Interventions | Lenalidomide (Revlimid®) |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2014 |
| Completion | Jun 1, 2014 |
| First posted | May 25, 2007 |
| Last update posted | Sep 18, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: